【制药网 行业动态】近年来，随着中国创新药研发能力的不断提升，对全球罕见病治疗领域发展也在不断贡献更多力量。2025年已有多个国产新药获得获得美国FDA孤儿药资格(“ODD”)，涵盖ADC、细胞治疗、基因治疗等多个前沿领域。值得一提的是，继7月17 日，弼领生物自主研发的 BL0020 注射液获得美国ODD，用于治疗小细胞肺癌(Small Cell Lung Cancer, SCLC)后，又有一款...
Source Link【制药网 行业动态】近年来，随着中国创新药研发能力的不断提升，对全球罕见病治疗领域发展也在不断贡献更多力量。2025年已有多个国产新药获得获得美国FDA孤儿药资格(“ODD”)，涵盖ADC、细胞治疗、基因治疗等多个前沿领域。值得一提的是，继7月17 日，弼领生物自主研发的 BL0020 注射液获得美国ODD，用于治疗小细胞肺癌(Small Cell Lung Cancer, SCLC)后，又有一款...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.